SPC Financial Inc. Acquires 400 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

SPC Financial Inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 10.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 4,212 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the period. SPC Financial Inc.’s holdings in Gilead Sciences were worth $309,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Creative Planning raised its position in Gilead Sciences by 0.5% during the 3rd quarter. Creative Planning now owns 152,961 shares of the biopharmaceutical company’s stock valued at $11,463,000 after purchasing an additional 767 shares in the last quarter. Tompkins Financial Corp raised its position in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. Public Sector Pension Investment Board raised its position in Gilead Sciences by 11.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 133,470 shares of the biopharmaceutical company’s stock valued at $10,002,000 after purchasing an additional 14,029 shares in the last quarter. EP Wealth Advisors LLC increased its holdings in shares of Gilead Sciences by 16.2% in the 3rd quarter. EP Wealth Advisors LLC now owns 47,110 shares of the biopharmaceutical company’s stock valued at $3,530,000 after acquiring an additional 6,560 shares during the period. Finally, Trust Co. of Vermont increased its holdings in shares of Gilead Sciences by 16.0% in the 3rd quarter. Trust Co. of Vermont now owns 8,266 shares of the biopharmaceutical company’s stock valued at $619,000 after acquiring an additional 1,139 shares during the period. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on GILD. Maxim Group cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a report on Monday. Finally, TD Cowen dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $84.00.

View Our Latest Analysis on Gilead Sciences

Gilead Sciences Price Performance

NASDAQ:GILD opened at $70.57 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The stock has a 50 day moving average of $66.32 and a two-hundred day moving average of $71.87. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The firm has a market cap of $87.92 billion, a P/E ratio of 194.36, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.37 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a $0.77 dividend. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.36%. Gilead Sciences’s payout ratio is 855.56%.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.